Agoracom Blog Home

Posts Tagged ‘CSE’

« Older Entries
Newer Entries »

Namaste $N.ca Announces Canada’s First Large-Scale National Prospective Observational Study to Observe the Impact of Medical #Cannabis Use for Anxiety Treatment $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 9:51 AM on Wednesday, April 4th, 2018

Nlogo

  • Initiated Canada’s first large-scale prospective study on a national platform called the Cannabis for Anxiety Reduction study, to determine the effectiveness of cannabis in reducing anxiety in study participants
  • One in four Canadians suffer from anxiety and the Company through this study will seek to gain valuable information from study participants on the impact of medical cannabis use in relation to their anxiety

VANCOUVER, British Columbia, April 04, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRANKFURT: M5BQ) (OTCMKTS:NXTTF) is pleased to announce that it has initiated Canada’s first large-scale prospective study on a national platform called the Cannabis for Anxiety Reduction study, to determine the effectiveness of cannabis in reducing anxiety in study participants. One in four Canadians suffer from anxiety and the Company through this study will seek to gain valuable information from study participants on the impact of medical cannabis use in relation to their anxiety. Namaste is also interested in determining the safety profile of patients using medical cannabis, and whether strain and dose of medical cannabis may impact patient reductions in anxiety ratings. The study will be available to all Canadians and will be conducted under the following conditions:

  • Prospective patients must be over 25 years of age.
  • Patients must score 8 or above Hospital Anxiety and Depression Scale (HADS).
  • The study will span over a 3-month period for each registered patient.
  • The study will be submitted for approval to the Veritas Independent Review Board (IRB) prior to commencement.
  • The primary investigator in the study is a nurse practitioner.
  • Patients can self-refer into the study (without referral through a doctor or specialist).

Namaste plans to offer this study to its patients which are registered under the Company’s wholly-owned subsidiary and virtual patient platform, NamasteMD Inc. (“NamasteMD”). Patients suffering from anxiety under the terms outlined above may participate in the study. This study is the first large-scale anxiety study in the nation, establishing Namaste as an innovator in research related to anxiety and cannabis. This is also the first national study where the primary investigator is a nurse practitioner. The Company intends to conduct similar studies in various areas where patients can benefit from the use of medical cannabis. The data collected from the study is valuable for the Company as well as the industry as a whole. The study may be published in peer-reviewed research journals and other medical publications.

For more information on this study please email [email protected]

Management Commentary

Sean Dollinger, President and CEO of Namaste comments; “We are very pleased to have initiated this study with the help of our partners at O-Cannabis. As many people in Canada suffer from varying forms of anxiety, we believe that many of these patients can benefit from the use of medical cannabis instead of prescription pharmaceutical drugs. We hope this study will provide very valuable information for Namaste and for the industry. We encourage qualifying patients to participate and look forward to seeing the results. We plan to undertake additional studies to bring awareness and a better understanding of how medical cannabis can benefit Canadians. We believe that these studies will help Namaste by attracting a larger base of patients and help solidify Namaste’s position as a leader in the Canadian medical cannabis industry.”

About Namaste Technologies Inc.

Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through 24 e-commerce sites in 20 countries and with distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: [email protected]

Further information on the Company and its products can be accessed through the links below:

NamasteTechnologies.com
NamasteMD.com
NamasteVapes.ca
Everyonedoesit.ca

FORWARD LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

 

Tags: , , , ,
Posted in All Recent Posts, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on Namaste $N.ca Announces Canada’s First Large-Scale National Prospective Observational Study to Observe the Impact of Medical #Cannabis Use for Anxiety Treatment $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Tetra Bio-Pharma $TBP.ca Initiates Enrollment of Patients in Phase 3 PPP001 Smokable Cannabis Pellet Study $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:58 AM on Wednesday, April 4th, 2018

Logo tetrabiopharma rgb web

  • Announced the initiation of screening and enrollment activities in the Phase 3 study of its PPP001 smokable cannabis pellet for advanced cancer patients with uncontrolled pain
  • Tetra authorized the initiation of the patient enrollment activities at its main clinical site, Santé Cannabis, a private medical cannabis clinic in Montreal which is in compliance with Health Canada Division 5 regulations and the International Conference on Harmonization (ICH) Good Clinical Practices (GCP) (E6) R2

1st Canadian Cannabis Smokable Pellet Study 1st Step Towards Pharmaceutical Distribution of Cannabis

OTTAWA, ONTARIO–(April 4, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP) (OTCQB:TBPMF), today announced the initiation of screening and enrolment activities in the Phase 3 study of its PPP001 smokable cannabis pellet for advanced cancer patients with uncontrolled pain.

Tetra authorized the initiation of the patient enrollment activities at its main clinical site, Santé Cannabis, a private medical cannabis clinic in Montreal which is in compliance with Health Canada Division 5 regulations and the International Conference on Harmonization (ICH) Good Clinical Practices (GCP) (E6) R2.

PPP001 aims to be the first smokable cannabis for advanced cancer pain available under prescription. It is a dried cannabis pellet designed to be smoked in an inhalation device specifically developed for this product. PPP001 is a unique blend of 3 strains of standardized dried cannabis, creating a drug substance with 9.5% THC and 2.5% CBD.

“This is a significant milestone in the lead product of our strong pipeline of cannabinoid-based drugs targeting patients with advanced pain,” said Guy Chamberland, Tetra’s CEO and CSO. “The launch of the Phase 3 clinical trial will be used to support the marketing application of PPP001 smokable pellet that is followed by four other cannabinoid-based products that we are developing using different delivery systems such as oral tablets, eye drops, topical ointments and oral capsules of cannabis oil.”

On February 28th, 2018, Santé Cannabis received authorization from the Office of Controlled Substances to use PPP001 (controlled substance) for the Phase 3 clinical trial. This authorization granted the Principal Investigator of the Phase 3 trial, Dr. Antonio Vigano, exemption from the application of several provisions of the Controlled Drugs and Substances Act and the Narcotic Control Regulations thereby allowing the investigator to proceed with the clinical study of PPP001 in advanced cancer patients. In addition, the exemption allows Santé Cannabis to store and dispense the study medication directly to the patients, a process not permitted by Licensed Producers under the ACMPR.

“We are performing the first large study of the safety and efficacy of a dried cannabis smoked drug in advanced cancer patients,” added Guy Chamberland. “Over the next month Tetra will expand the trial by working with other clinics across Canada. Most importantly, we believe this multisite study has the potential to change the current vision of the use of smoked cannabis as an effective palliative care therapy of patients with advanced cancer.”

About PPP001:

PPP001 aims to be the first smokable marihuana for advanced cancer pain under prescription. It is a dried cannabis pellet designed to be smoked in an inhalation device specifically developed for this product. PPP001 is a unique blend of 3 strains of standardized dried cannabis, creating a drug substance with 9.5% THC and 2.5% CBD.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the failure to obtain sufficient financing to execute the Corporation’s business plan; the success of the Rx Princeps™ product offering and inhalation device; guidance on expected sales volumes associated with the Rx Princeps™ product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(438) 899-7575

For media information, please contact:
Daniel Granger
[email protected]
ACJ Communication
O: 1 514 840 7990
M: 1 514 232 1556

For investors information, please contact:
[email protected]
(438) 504-5784

Tags: , , ,
Posted in All Recent Posts, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Initiates Enrollment of Patients in Phase 3 PPP001 Smokable Cannabis Pellet Study $AERO $CBDS $CGRW $APH.ca $GBLX

#NBA2K League Draft: TV And Stream Info For Wednesday’s Event #Esports $GMBL $KUU.ca

Posted by AGORACOM-JC at 8:49 AM on Wednesday, April 4th, 2018
Brian Mazique , Contributor Opinions expressed by Forbes Contributors are their own.

If you were wondering how you can watch the first-ever NBA 2K League, here are your answers.

  • live pre-draft press conference featuring NBA Commissioner Adam Silver, NBA 2K League Managing Director Brendan Donohue, and Take-Two Interactive Chief Executive Officer Strauss Zelnick
  • begins at 12 pm ET and can be seen on NBA TV, the NBA App, NBA.com, and the NBA 2K League Twitter handle.

NBA 2K League Draft Lottery

There will be a live pre-draft press conference featuring NBA Commissioner Adam Silver, NBA 2K League Managing Director Brendan Donohue, and Take-Two Interactive Chief Executive Officer Strauss Zelnick. That begins at 12 pm ET and can be seen on NBA TV, the NBA App, NBA.com, and the NBA 2K League Twitter handle. Silver will announce the league’s first overall pick.

At 1 pm ET, the draft will begin. The entire first round can be seen on NBA TV and the NBA 2K League’s official Twitch channel. The second through sixth rounds will be streamed on Twitch exclusively. There are 17 teams and each will select six players. The draft will progress in a serpentine order until the final pick is announced.

Follow me on Twitter, like my Facebook page and subscribe to my YouTube channel.

Source: https://www.forbes.com/sites/brianmazique/2018/04/04/nba-2k-league-draft-tv-and-stream-info-for-wednesdays-event/#348df2736f93

Tags: , , ,
Posted in All Recent Posts, Esports Entertainment Group, Esports Entertainment Group Inc., Kuuhubb | Comments Off on #NBA2K League Draft: TV And Stream Info For Wednesday’s Event #Esports $GMBL $KUU.ca

Could medical #marijuana help curb the #opioid crisis? #MMJ $N.ca $TBP.ca $MCOA

Posted by AGORACOM-JC at 5:10 PM on Tuesday, April 3rd, 2018
  • Medical marijuana could help quell the ongoing opioid epidemic, a pair of new studies contends.
  • Opioid prescriptions tend to decrease in U.S. states that adopt medical marijuana laws or legalize recreational use of pot, two different research teams have concluded.

The studies couldn’t prove cause and effect. But one study found that opioids dispensed through Medicare’s prescription drug plan decreased significantly if people had access to medical pot dispensaries or were allowed to grow marijuana for their own use.

“We had about a 14.5 percent reduction in opiate use when states turned on dispensaries, and about a 7 percent reduction in opiate use when states turned on home cultivation-based cannabis laws,” said researcher David Bradford, chairman of public policy at the University of Georgia School of Public and International Affairs.

The other study, led by researcher Hefei Wen, from the University of Kentucky College of Public Health, found a decrease in opioid prescriptions covered by Medicaid in states that legalized either medicinal or recreational pot.

Both types of laws were linked to about a 6 percent decline in opioid prescribing, researchers reported.

“We do think there’s good reason to be hopeful that cannabis might be one tool out of many we could use to address the opioid epidemic,” Bradford said.

Drug overdoses killed nearly 64,000 Americans in 2016, with two-thirds of deaths involving a prescription or illicit opioid, the U.S. Centers for Disease Control and Prevention reported last week. Overdose deaths rose 21.5 percent in 2016, a much sharper spike than the 11.4 percent increase seen the previous year.

At this point, 30 states and the District of Columbia have laws legalizing some form of marijuana use, including eight states that have legalized recreational use.

Studies have found medical pot is effective in treating chronic pain, Bradford said. In 2017, the prestigious National Academies of Sciences, Engineering and Medicine issued a report concluding that pot can significantly reduce pain symptoms.

Both research teams suspected that if this were true, then medical marijuana might ease opioid use in people with chronic pain.

To investigate this theory, the investigators turned to recent data from the federal insurance programs Medicare and Medicaid. They compared opioid prescribing patterns between states with medical or recreational pot and those that have taken a hard line against weed.

An average state filled 23 million daily doses of opioids through Medicare’s prescription drug plan between 2010 and 2015, Bradford’s team found.

But states with medical pot dispensaries filled 3.7 million fewer daily doses, and states with home cultivation filled 1.8 million fewer doses, they said.

Results did vary based on the type of opioid, however. Medical pot was linked to reductions in hydrocodone, morphine and fentanyl prescriptions, but not to prescriptions for oxycodone, Bradford said. The second study found a similar effect among people covered by Medicaid.

The two studies were published online April 2 in JAMA Internal Medicine.

“I think at this point, with patients dying every day as a result of opioid use disorder, we need to consider all possible solutions to the crisis,” said Dr. Kevin Hill, director of addiction psychiatry at Beth Israel Deaconess Medical Center in Boston and an assistant professor of psychiatry at Harvard Medical School. “Papers like these two suggest that cannabis may play a role.”

He said these studies and others offer strong support for anecdotal evidence from patients who report they need fewer opioids for chronic pain when they are put on medical cannabis. Hill wrote an editorial that accompanied the two articles.

At the same time, Hill says medical marijuana should not be given a lead role in treating chronic pain. Instead, it should be a back-up option for patients who are struggling to manage pain and who could be in danger of addiction.

“I think it’s hard to deny that there is a growing body of evidence that suggests a role for cannabis in treating chronic pain, but it’s not the level where it would be a first-line or even second-line treatment,” Hill said.

Source: https://www.cbsnews.com/news/could-medical-marijuana-help-curb-the-opioid-crisis/

Tags: , , ,
Posted in All Recent Posts, Marijuana Company of America, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on Could medical #marijuana help curb the #opioid crisis? #MMJ $N.ca $TBP.ca $MCOA

Seriously, There’s Still a 400% Arbitrage Opportunity and it Just Got Less Risky #betterU $BTRU.ca

Posted by AGORACOM-JC at 3:36 PM on Tuesday, April 3rd, 2018

 

Seriously, There’s Still a 400% Arbitrage Opportunity and it Just Got Less Risky

 

Today – that US$100 million mega deal between BetterU Education Corp. (CVE:BTRU, FRA:5OGA, Mkt Cap: C$43M) and Treasure Union Ltd. (TU) is one step closer to completion.

The Chairman of TUCapital, Kenny Ho, has confirmed that TUCapital has executed on the Subscription Agreement as of April 3rd, 2018. The creation of TUCapital was one of the initiatives highlighted in the final definitive agreement.

BetterU’s Chairman, Tony Keenan, is currently in Guangzhou, China with Mr. Ho coordinating the details of the fund transfer – which is expected to be completed in just 2-3 weeks.

The market may still be iffy as the deal was expected to be completed by March. However, it is important to note deals of this size require the approval of banking institutions and regulators – which ultimately impact the timeline.

This lets contrarian investors take advantage of the crowds’ impatience and doubts.

We also want to mention that Treasure Union Ltd. recently completed a US$50 million Series B funding round with Toronto-based Loraxian Inc., a global renewable energy and infrastructure company. . .

This shows us that Treasure Union has – and is deploying – cash.

We expect in 2-3 weeks BetterU will complete the financing.

At the current price – that’s still 400% upside.

Source: https://mailchi.mp/fe9885407a47/seriously-theres-still-a-400-arbitrage-opportunity-and-it-just-got-less-risky?e=4773499894

Tags: , , ,
Posted in All Recent Posts, betterU Education Corp | Comments Off on Seriously, There’s Still a 400% Arbitrage Opportunity and it Just Got Less Risky #betterU $BTRU.ca

Tetra Bio-Pharma $TBP.ca Names Guy Chamberland as Interim CEO $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 2:09 PM on Tuesday, April 3rd, 2018

Logo tetrabiopharma rgb web

  • Announced the appointment of Guy Chamberland, M.Sc., Ph.D., an accomplished drug developer, as interim Chief Executive Officer (CEO)
  • Appointment is effective immediately

OTTAWA, ONTARIO–(April 3, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced the appointment of Guy Chamberland, M.Sc., Ph.D., an accomplished drug developer, as interim Chief Executive Officer (CEO). This appointment is effective immediately.

Dr. Chamberland has been Chief Scientific Officer & Regulatory Affairs of Tetra since June 2016. He has over 23 years’ experience in the development of new drugs in the pharmaceutical industry (Canada and USA). He worked more than 10 years as an executive in various biopharmaceutical companies and was a member of the investment committee of a venture capital fund for 7 years.

Tetra’s former CEO, Bernard Fortier, left the corporation today thereby terminating his role as Chief Executive Officer and member of the Board of Directors.

“We are thankful for Bernard’s contributions to Tetra’s activities,” stated André Rancourt, Chairman of the Board. “Guy’s role as interim CEO will be a tremendous asset at this stage of Tetra’s growth. He will maintain his role and responsibility as Chief Scientific Officer while ensuring the growth and strategic operations of the corporation.”

Chamberland will serve as interim Chief Executive Officer while the Board of Directors conducts a search for a new Chief Executive Officer.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the failure to obtain sufficient financing to execute the Corporation’s business plan; the success of the Rx Princeps™ product offering and inhalation device; guidance on expected sales volumes associated with the Rx Princeps™ product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(438) 899-7575

For investors information, please contact:
[email protected]
(438) 504-5784

Tags: , , ,
Posted in All Recent Posts, Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Names Guy Chamberland as Interim CEO $AERO $CBDS $CGRW $APH.ca $GBLX

INTERVIEW: Esports Entertainment Group $GMBL Discusses Launch Of VIE.GG, The World’s Safest, Most Secure and Transparent #Esports Wagering Platform $ATVI $TTWO $GAME $EPY.ca

Posted by AGORACOM-JC at 11:25 AM on Tuesday, April 3rd, 2018

Tags: , , , , ,
Posted in AGORACOM Via Satellite, All Recent Posts, Esports Entertainment Group, Esports Entertainment Group Inc. | Comments Off on INTERVIEW: Esports Entertainment Group $GMBL Discusses Launch Of VIE.GG, The World’s Safest, Most Secure and Transparent #Esports Wagering Platform $ATVI $TTWO $GAME $EPY.ca

PyroGenesis $PYR.ca to Present at The #MicroCap Conference on April 9th in New York City

Posted by AGORACOM-JC at 10:20 AM on Tuesday, April 3rd, 2018

Pyr header 1

  • Presenting at this year’s MicroCap Conference on April 9th at 12:00 PM ET at the Essex House in New York City.
  • MicroCap Conference provides a unique opportunity to meet one-on-one with management of some of the most attractive companies, network with other like-minded investors

MONTREAL, QC / April 3, 2018 / PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX-V: PYR), (the ”Company,” the ”Corporation” or ”PyroGenesis”) a Company that designs, develops and manufactures plasma waste-to-energy systems and plasma torch systems, announced today that Peter Pascali, CEO & President of PyroGenesis will be presenting at this year’s MicroCap Conference on April 9th at 12:00 PM ET at the Essex House in New York City.

About MicroCap Conference

The MicroCap Conference provides a unique opportunity to meet one-on-one with management of some of the most attractive companies, network with other like-minded investors, and sharpen your skills by learning from our industry panels and expert speakers. This event will bring together over 120 presenting companies across sectors, and north of 600 attendees from the micro-cap investment community.

FOR MORE INFORMATION

Please visit: www.microcapconf.com
Or, contact Tony Yu, CEO at [email protected].

News Compliments of ACCESSWIRE.

About PyroGenesis Canada Inc.

PyroGenesis Canada Inc. is the world leader in the design, development, manufacture and commercialization of advanced plasma processes. We provide engineering and manufacturing expertise, cutting-edge contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, advanced materials (including 3D printing), oil & gas, and environmental industries. With a team of experienced engineers, scientists and technicians working out of our Montreal office and our 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. Our core competencies allow PyroGenesis to lead the way in providing innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. Our operations are ISO 9001:2008 certified, and have been since 1997. PyroGenesis is a publicly-traded Canadian Corporation on the TSX Venture Exchange (Ticker Symbol: PYR) and on the OTCQB Marketplace. For more information, please visit www.pyrogenesis.com.

For further information please contact: Rodayna Kafal, VP, Investor Relations and Strategic Business Development, Phone: (514) 937-0002, E-mail: [email protected].

RELATED LINKS: http://www.pyrogenesis.com/.

SOURCE: PyroGenesis Canada Inc.

Tags: , , , ,
Posted in All Recent Posts, PyroGenesis Canada Inc. | Comments Off on PyroGenesis $PYR.ca to Present at The #MicroCap Conference on April 9th in New York City

betterU Education Corporation $BTRU.ca Provides Update on Closing of US$100 Million Investment $ARCL $BPI $FC.ca

Posted by AGORACOM-JC at 9:17 AM on Tuesday, April 3rd, 2018

Betteru large

  • Chairman of TUCapital, Kenny Ho, has confirmed to the Corporation that TUCapital has been established and that they have executed on the Subscription Agreement as of April 3rd, 2018
  • betterU’s Board of Directors Chairman Tony Keenan is currently in Guangzhou, China with Mr. Ho coordinating the details of the fund transfer
  • Expected to be within the upcoming 2-3 weeks subject to banking and legal requirements

OTTAWA, April 03, 2018 — betterU Education Corp. (TSX-V:BTRU) (FRANKFURT:5OGA) (the “Corporation” or “betterU”) is pleased to provide an update on the closing of the US$100M equity investment last announced on February 8th, 2018.

The Chairman of TUCapital, Kenny Ho, has confirmed to the Corporation that TUCapital (the ‘Fund’) has been established and that they have executed on the Subscription Agreement as of April 3rd, 2018. betterU’s Board of Directors Chairman Tony Keenan is currently in Guangzhou, China with Mr. Ho coordinating the details of the fund transfer which is expected to be within the upcoming 2-3 weeks subject to banking and legal requirements. The Corporation had previously announced that the agreements were to be completed by the end of March; however, deals of this size and nature do involve many people from multiple countries, processes, paperwork, banks and legal approvals which has had an impact on timelines. The Corporation has also been working with their own legal and banking teams in preparation for receipt of funds. Once funds have been received, the Corporation will update the market to the issuance the shares, subject to legal and governing body approvals.

The consummation of any financing, as contemplated, remains subject to TSXV approval, and among other conditions of the TSXV’s approval, disinterested shareholder approval.

About betterU

betterU, a global education to employment platform, aims to provide access to quality education from around the world to foster growth and opportunity to those who want to better their lives. The company plans to bridge the prevailing gap in the education and job industry and enhance the lives of its prospective learners by developing an integrated education-to-employment ecosystem. betterU’s offerings can be categorized into several broad functions: to complement school programs with flexible KG-12 programs preparing children for next stage of education, to provide access to global educational opportunities from leading educators, to foster an exceptional educational environment by providing befitting skills that lead to a better career, to bridge the gap between one’s existing education and prospective job requirement by training them and lastly, to connect the end user to various job opportunities.

www.betterU.ca and www.betterU.in

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release may contain forward-looking statements and information, which may involve risks and uncertainties. The results or events predicted in these statements may differ materially from actual results or events. Factors that might cause a difference include, but are not limited to, competitive developments, risks associated with betterU’s growth, the state of the financial markets, regulatory risks and other factors. There can be no assurance or guarantees that any statements of forward-looking information contained in this release will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral statements containing forward-looking information are based on the estimates and opinions of management on the dates they are made and expressly qualified in their entirety by this notice. Unless otherwise required by applicable securities laws, betterU disclaims any intention or obligation to update or revise any forward-looking statements, whether because of new information, future events or otherwise. Readers should not place undue reliance on any statements of forward-looking information that speak only as of the date of this release. Further information on betterU’s public filings, including their most recent audited consolidated financial statements, are available at www.sedar.com.

For further information, please visit https://ir.betteru.ca/investor-overview/press-releases/

On behalf of the Board of Directors,
better Education Corp.
Brad Loiselle, CEO

For further information:

Investor Relations
1-613-695-4100 Ext. 233
Email: [email protected]

Tags: , , , , ,
Posted in All Recent Posts, Featured | Comments Off on betterU Education Corporation $BTRU.ca Provides Update on Closing of US$100 Million Investment $ARCL $BPI $FC.ca

Gratomic Inc $GRAT.ca Gratomic Announces 6.88% Cg Over 62 Metres at 100% Owned Buckingham Project #Graphite

Posted by AGORACOM-JC at 8:55 AM on Tuesday, April 3rd, 2018

Gratomic large new

  •  %100 owned Buckingham graphite project in Quebec
  •  16.64% Cg  over 18 metres in drill hole CK18-07
  • 4.94% Cg was intersected over 66 metres in Hole CK18-09

TORONTO, April 03, 2018 (GLOBE NEWSWIRE) — Gratomic Inc. (“Gratomic” or the “Company”) (TSX-V:GRAT) (FRANKFURT:CB81) a vertically integrated graphite to graphenes, advanced materials development company is pleased to provide results from the diamond drilling program at its 100% owned Buckingham graphite project in Quebec. Results have now been received from all six holes, with assays up to 16.64% Cg (carbon as graphite) over 18 metres in drill hole CK18-07.

Gratomic’s Co-CEO Arno Brand stated, “The Buckingham results are inspiring and further validate that this asset has significant exploration merit.”

Highlights of the results received to date include a grade of 6.88% Cg over 62 metres in hole CK18-07, that included 12.75% Cg over 29 metres and included a higher grade 16.64% Cg interval over 18 metres, starting at a depth of 57 metres. A grade of 4.94% Cg was intersected over 66 metres in Hole CK18-09 from six metres, that included higher grade near surface intervals of 14.52% Cg over four metres and 13.52% Cg over three metres. A summary of the results is given in the table below.

 

The drilling follows up on positive results of previous work including airborne electromagnetics, trenching and a first stage drill program undertaken during 2016 and 2017. Hole CK-18-06 was drilled to the northwest to test the thickest portion of the 1.54 kilometre long northeast-southwest trending electromagnetic (EM) conductor and intersected low grade graphite mineralization associated with carbonate horizons in quartzo-feldspatic gneiss. Hole CK 18-07 was drilled to the southeast through the conductor between trenches 5 and 6 from the 2017 program. The hole intersected three graphite zones between 30 and 146 metres, with the highest grades associated with marble zones within gneiss. Hole CK18-08 was collared approximately 50m north of hole CK18-06 and drilled to the southeast. It intersected two graphite zones from 46 to 63 metres and from 95 to 108 metres with higher grades again associated with marble horizons. Hole CK18-09 was drilled to the northwest across a narrowing of the EM anomaly and intersected three graphite zones between 6 metres and 157 metres. Graphite mineralization in the near surface zone is associated with intervals of marble within the gneiss. Holes CK18-10 and CK18-11 were drilled across conductors in the vicinity of trench 2 and trench 10, respectively. Both holes showed relatively narrow intervals of graphite associated with marble.

All samples were placed in a plastic sample bag along with a sample tag. Bags were sealed with a single use tie. Samples were securely stored prior to shipping to SGS in Lakefield Ontario. Samples were crushed, milled and roasted and treated by HCl leach prior to being assayed by the combustion infrared technique (LECO). The Company routinely submits standards, duplicates and blanks with sample batches to monitor the quality of the assays.

The technical content of this News Release was reviewed and approved by Roger Moss Ph.D., P.Geo, a qualified person as defined by National Instrument 43-101.

About Gratomic Inc.
Gratomic is an advanced materials company focused on mine to market commercialization of graphite products most notably high value graphene based components for a range of mass market products. We are collaborating with a leading European manufacturer of graphenes to use Aukam graphite to manufacture graphene products for commercialization on an industrial scale. The company is listed on the TSX Venture Exchange under the symbol GRAT.

About the Buckingham Project

The 100%-owned Buckingham Graphite Property is located 7 kilometres northwest of the town of Buckingham, Quebec, Canada and consists of eight claim blocks totaling 480 hectares. Well-maintained bush roads provide easy access to the property. The property lies within the Central Metasedimentary Belt of the Grenville Geologic Province 82 km south of Imerys Graphite & Carbon’s operating Lac des Iles graphite mine. Graphite occurs disseminated in marble and paragneiss and within veins hosted in pegmatite, diopside skarn, marble and gneiss.

Two graphitic zones, the Uncle Zone and the Case Zone have been discovered to date, with both zones showing high grade occurrences of disseminated flake and vein type graphite and yielding assay values as high as 81.1% Cg. Initial crushing and flotation of two samples from the Uncle Zone has achieved purity of up to 99.4% Cg from a single flotation test without process optimization (see news release dated February 17, 2015).

For more information: visit the website at www.gratomic.ca or contact:
Arno Brand, Co-CEO, +1 416-561-4095

E-mail inquiries: [email protected]

Tags: , , , , , ,
Posted in Featured, Graphite | Comments Off on Gratomic Inc $GRAT.ca Gratomic Announces 6.88% Cg Over 62 Metres at 100% Owned Buckingham Project #Graphite

« Older Entries
Newer Entries »